Fan, Ming, Weixi Qin, and S. Jamal Mustafa. Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol 284: L1012-L1019, 2003. First published January 17, 2003 10.1152/ajplung.00353.2002We recently reported that adenosine caused bronchoconstriction and enhanced airway inflammation in an allergic mouse model. In this study, we further report the characterization of the subtype of adenosine receptor(s) involved in bronchoconstriction. 5Ј-(N-ethylcarboxamido)adenosine (NECA), a nonselective adenosine agonist, elicited bronchoconstriction in a dose-dependent manner. Little effects of N 6 -cyclopentyladenosine (A1-selective agonist) and 2-p-(2-carboxyethyl)phenethylamino-5Ј-Nethylcarboxamidoadenosine (A2A-selective agonist) compared with NECA were observed in this model. 2-Chloro-N 6 -(3-iodobenzyl)-9-[5-(methylcarbamoyl)-␤-D-ribofuranosyl]adenosine, an A3-selective receptor agonist, produced a dose-dependent bronchoconstrictor response, which was blocked by selective A3 antagonist 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate (MRS1523). However, MRS1523 only partially inhibited NECA-induced bronchoconstriction. Neither selective A1 nor A2A antagonists affected NECA-induced bronchoconstriction. Enprofylline, a relatively selective A2B receptor antagonist, blocked partly NECA-induced bronchoconstriction. Furthermore, a combination of enprofylline and MRS1523 completely abolished NECA-induced bronchoconstrictor response. Using RT-PCR, we found that all four adenosine receptor subtypes are expressed in control lungs. Allergen sensitization and challenge significantly increased transcript levels of the A2B and A3 receptors, whereas the A1 receptor message decreased. No change in transcript levels of A2A receptors was observed after allergen sensitization and challenge. These findings suggest that A2B and A3 adenosine receptors play an important role in adenosine-induced bronchoconstriction in our allergic mouse model. Finally, whether the airway effects of the receptor agonists/antagonists are direct or indirect needs further investigations. adenosine agonists; adenosine antagonists; mouse lung; asthma AMONG THE MANY ACTIONS of adenosine, several lines of evidence suggest a contribution of adenosine to the pathophysiology of asthma. Adenosine is present in high concentrations in the bronchoalveolar lavage fluid of asthmatics (8). Airway preparations from allergic asthmatic subjects are more sensitive to the contractile responses of adenosine and related analogs (4). Inhaled adenosine causes bronchoconstriction in asthmatics and allergic nonasthmatics compared with normal subjects (24).
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The response of the asthmatic airways to adenosine involves the activation of extracellular adenosine receptor(s). Theophylline, a nonselective adenosine receptor antagonist, selectively (relative to histamine) inhibited adenosine-induced bronchoconstriction at doses generating plasma concentrations that are insufficient to inhibit phosphodiesterases but well above those needed to block adenosine receptors (22) . Moreover, both rebound hyperresponsiveness to adenosine and exacerbation of symptoms have been reported when chronic theophylline therapy was withdrawn (36) .
Adenosine receptors are seven-transmembranespanning receptors that are coupled to the effector system through heterotrimeric G proteins. Four subtypes of adenosine receptors, A 1 , A 2A , A 2B , and A 3 , have been identified based on the order of agonist potency and antagonist affinity, G protein coupling, cellular responses, and receptor cloning studies (11) . Each of these receptor subtypes is expressed in lung and may have a role in asthma.
Most evidence indicates that activation of the A 1 receptors, and to some extent the A 3 receptors, induces adenylyl cyclase inhibition with subsequent decrease in adenosine 3Ј,5Ј-cyclic monophosphate (cAMP) level. This intracellular signal induces contraction of the airway smooth muscle. In contrast, when adenosine activates the A 2A receptors, cAMP level increases, which causes airway relaxation (29) . Adenosine A 2B receptors have long been known to be coupled to G s protein, which mediates the activation of adenylyl cyclase (12, 33) . Recent studies indicate that A 2B receptors are also coupled to G q and result in Ca 2ϩ mobilization and mitogen-activated protein kinase activation (20, 21) . Also, the A 3 receptors have been suggested to mediate the facilitation of antigen-induced release of bronchoconstrictor mediators through inositol triphosphate and the Ca 2ϩ pathway (34) . Despite the pivotal role that adenosine receptors play in bronchoconstriction and inflammatory reactions under allergic conditions, the subtype(s) of adenosine receptors mediating bronchoconstriction remain poorly defined. The accumulated evidence shows that the receptor subtype varies widely among species, for example, the involvement of A 3 receptors in the guinea pig (18) , A 1 receptors on airway smooth muscle cell in the rabbit (28) , and a combination of A 1 , A 2B , and A 3 receptors in the BDE rat (31) . In mice, our data (9) and those of others (6) have shown that exogenous and endogenous adenosine mediates bronchoconstriction and airway hyperresponsiveness through specific adenosine receptors, but the relative contribution of each adenosine receptor subtype mediating bronchoconstriction in mice is still unresolved.
The present study was initiated following our previous study demonstrating that ragweed sensitization and challenge of mice induced a profound increase in bronchoconstrictor response to adenosine and lung inflammation (9) . Here, we investigated the involvement of the subtype of adenosine receptor(s) mediating bronchoconstriction to adenosine using selective adenosine receptor agonists and antagonists and studied a profile of adenosine receptor expression in allergic mouse lung using RT-PCR.
MATERIALS AND METHODS

Mice and Sensitization
Male BALB/c mice, 6-8 wk of age and free of specific pathogens, were obtained from Harlan Laboratories (Indianapolis, IN). The animals were maintained on a ragweed-free diet. All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of East Carolina University.
Sensitization was performed according to a method described previously (9) . In brief, mice were sensitized with two intraperitoneal injections of ragweed allergen (Greer Laboratories, Lenoir, NC), 200 g per dose with 200 l of Imject alum (Pierce Laboratories, Rockford, IL) on days 1 and 6. Nonsensitized control animals received only the Imject alum with the same volumes. After sensitization, the mice were placed in a Plexiglas chamber and challenged with 0.5% aerosolized ragweed or with 0.9% saline as a control, via an ultrasonic nebulizer (DeVilbiss, Somerset, PA) for 20 min both in the morning and afternoon on days 11, 12, and 13.
Experimental Protocol
Airway responsiveness to adenosine agonists. Airway responsiveness was assessed with whole body plethysmograph (Max II; Buxco, Troy, NY). This system estimates total pulmonary air flow using a dimensionless parameter known as enhanced pause (Penh). Pressure differences were used to extrapolate Penh value, which is a function of the sum of the air flows in the upper and lower respiratory tracts during a respiratory cycle. Penh has been shown to correlate with direct measurement of airway obstruction (lung resistance and dynamic compliance) (17) . Twenty-four hours after the last challenge with aerosolized ragweed or saline, mice were placed in the chamber and exposed to adenosine agonists 5Ј-(N-ethylcarboxamido)adenosine (NECA, a nonselective adenosine receptor agonist), N 6 -cyclopentyladenosine (CPA, a selective A1 adenosine receptor agonist) in 10% ethanol, 3 adenosine receptor agonist) in 20% DMSO via Buxco Aerosol Delivery System (version 1.5; Buxco, Sharon, CT) at 2.5 l/min of the dilution flow and 0.15 l/min of the trickle flow for 2 min at increasing concentrations (11.72-375 g/ml) for dose responsiveness. The next dose was not given until the animal returned to baseline Penh. Airway responsiveness was expressed as percentage increase in Penh compared with vehicle. Readings were taken for 5 min following each nebulization. For the quantification of the dose responsiveness to adenosine agonists, the linear regression of Penh was calculated for individual mice. The dose corresponding to an increase in Penh of 100% (EC 100) was determined, and average dose in different groups was compared by analysis of variance.
Adenosine antagonist challenges. Adenosine antagonists
Ϫ4 M) in 20% DMSO were aerosolized with the Buxco Aerosol Delivery System at 2.5 l/min of the dilution flow and 0.15 l/min of the trickle flow for 5 min. After 15 min, dose responsiveness to a corresponding adenosine agonist and NECA was performed in the same manner as mentioned above. Pulmonary measurements were recorded before and after pretreatment with an adenosine antagonist to determine its effect on basal bronchial tone. Also, the effect of vehicle per se on Penh was examined.
RT-PCR. Mice were immunized with the protocol described above. Twenty-four hours after the last challenge with aerosolized allergen or 0.9% saline, mice were killed by injection (0.1 ml pentobarbitone sodium 200 mg/ml ip). Lungs were taken and immediately frozen in liquid nitrogen. Total RNA was isolated from the mouse lung of both ragweedsensitized and -challenged mice and control animals with TRIzol reagent (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's instructions, and RT-PCR was conducted as described earlier (5) . Briefly, for the RT reaction, 5 g of purified total RNA were reverse transcribed in the presence of an anchored oligo-p (dT)15 primer, by use of avian myeloblastosis virus RT (Roche Diagnostics) based on the manufacturer's recommendations. Sets of specific primers for adenosine receptors for A1 (37) , A2A (15), A2B (5), and A3 (3) are presented in Table 1 .
Single-stranded cDNA products were denatured and subjected to PCR amplification (35 cycles). Each PCR cycle consisted of denaturing at 94°C for 5 min (for A1 and A2B receptors) and at 94°C for 3 min (for A2A and A3 receptors), annealing at 60°C for 1 min (for A2A, A2B, and A3 receptors) and at 65°C for 30 s (for A1 receptors), extension at 72°C for 2 min (for A1 and A2B receptors) and at 72°C for 1 min (for A2A and A3 receptors). A final extension of 72°C for 7 min (for A1 and A2B receptors) and of 72°C for 10 min (for A2A and A3 receptors) was added after the 35th amplification cycle.
The reaction mixture contained 0.2 mM 2-deoxynucleotide 5Ј-triphosphate, 2.5 U/100 l Taq DNA polymerase (Roche Diagnostics), and 1ϫ PCR buffer (1.5 mM Mg 2ϩ ) with GeneAmp PCR system (model 9600; Perkin-Elmer). Amplification of ␤-actin mRNA served as control. The PCR products were separated on 2.5% agarose gels with ethidium bromide. The resulting data were analyzed using FluorChem digital Imaging System with AlphaEaseFC software (Alpha Innotech, San Leandro, CA). The relative expression level of adenosine receptor mRNA was calculated compared with ␤-actin. Results are expressed as means Ϯ SE. 
Statistical Analysis
Experimental values are presented as means Ϯ SE. EC 100 was calculated. Analysis of variance was used to determine the level of significance among all groups. Pairs of groups were compared with unpaired two-tailed Student's t-test. The P value for significance was set at 0.05.
RESULTS
Dose Responsiveness to Adenosine Receptor Agonists and the Effect of Corresponding Adenosine Receptor Antagonists
Aerosol challenge with NECA, a nonselective adenosine receptor agonist, elicited a dose-dependent increase in Penh in both ragweed-sensitized and -challenged and control mice. Bronchoconstrictor responsiveness to NECA was significantly enhanced in allergen-sensitized and -challenged mice compared with the controls. The maximum responsiveness to NECA (375 g/ml) was 405.9 Ϯ 35.6% in sensitized and challenged mice and 181.8 Ϯ 7.7% in controls, respectively (P Ͻ 0.001). The EC 100 was 30.66 g/ml (95% confidence limits: 24.75-36.58) in ragweed-sensitized and -challenged mice and 142.03 g/ml (95% confidence limits: 124.47-159.60) in control animals, respectively (P Ͻ 0.001, Fig. 1 ). The baseline Penh values between control (0.72 Ϯ 0.06) and ragweed-sensitized and -challenged mice (0.78 Ϯ 0.05) were not different. Vehicle (10% ethanol aerosolized for 2 min) used in experiment with agonists had no significant effect on Penh in both control and immunized mice. Also, 10% ethanol aerosolized for 5 min (vehicle for antagonists) was without an effect on basal bronchial tone.
Because NECA, like adenosine, has affinity for each of the four adenosine receptor subtypes (19) , the question arises as to which adenosine receptor subtype is being activated in NECA-induced bronchoconstriction. To distinguish the subtype of adenosine receptors involved in NECA-induced bronchoconstrictor responsiveness, we employed selective adenosine agonists and antagonists. CPA is a potent and selective agonist at A 1 receptors with reported inhibitor constant (K i ) values of 0.59, 460, and 240 nM at rat A 1 , A 2A , and A 3 receptors, respectively (11) . Aerosol challenge of mice with CPA elicited little change in Penh in both control and immunized mice (Fig. 2A) . Further experimentation was done to examine the bronchoconstrictor responsiveness to NECA with a selective A 1 receptor antagonist, DPCPX, for which the K i values at rat A 1 , A 2A , and A 3 receptors are 0.3 nM, 340 nM, and Ͼ10 M, respectively (11) . There was no effect of DPCPX on dose responsiveness to NECA observed after mice were pretreated with DPCPX (Fig. 2B ). DPCPX per se had no effect on baseline Penh in both groups. Penh values before and after DPCPX under baseline conditions were 0.68 Ϯ 0.03 and 0.62 Ϯ 0.05 in control animals and 0.73 Ϯ 0.06 and 0.67 Ϯ 0.08 in sensitized and challenged mice, respectively (P Ͼ 0.05).
CGS21680 is the most potent, highly selective agonist at A 2A receptors and is the ligand of choice for the characterization of A 2A receptors. Aerosol challenge with CGS21680 did not affect the Penh (Fig. 3A) . Pretreatment with an A 2A receptor antagonist, SCH58261, a potent and highly selective A 2A receptor antagonist both in vivo and in vitro (30) , was unable to alter the bronchoconstrictor dose-response curve to NECA in either control or sensitized and challenged groups ( (11) . CL-IB-MECA challenge produced marked bronchoconstrictor responsiveness in a dose-dependent manner (Fig. 4A) . The maximum responsiveness to CL-IB-MECA (375 g/ml) was 334.2 Ϯ 34.6% in sensitized and challenged mice and 169 Ϯ 19.4% in controls, respectively (P Ͻ 0.001). The EC 100 dose of CL-IB-MECA was 62.81 g/ml (95% confidence limits: 52.52-73.10) in ragweed-sensitized and -challenged mice and 158.55 g/ml (95% confidence limits: 121.75-195.35) in control animals, respectively. CL-IB-MECA-induced bronchoconstrictor responsiveness was completely inhibited by an A 3 -selective antagonist, MRS1523, that is effective in various species (11) (Fig. 4A) . MRS1523 itself did not affect basal bronchial tone. The basal Penh values before and after pretreatment with MRS1523 were 0.61 Ϯ 0.03 and 0.72 Ϯ 0.09 in control mice (P Ͼ 0.05) and in sensitized and challenged animals were 0.71 Ϯ 0.05 and 0.64 Ϯ 0.07 (P Ͼ 0.05), respectively. Vehicle alone (20% DMSO aerosolized for 2 or 5 min) had no effect on Penh in both control and allergen-sensitized and -challenged mice.
Furthermore, the effect of MRS1523 on a dose-response curve for NECA was also tested. It was found that NECA-induced bronchoconstriction was partially inhibited by MRS1523 (Fig. 4B) , especially at the highest concentration (375 g/ml of NECA). This suggests the involvement of other adenosine receptors, possibly the A 2B receptors, in addition to A 3 receptors.
Because there is a lack of availability of A 2B -selective antagonists commercially, enprofylline, which is somewhat selective for A 2B adenosine receptors with K i values of 156, 32, 7, and 65 M at human A 1 , A 2A , A 2B , and A 3 receptors, respectively (10), was used to examine the effect of A 2B receptors in NECA-induced bronchoconstrictor responsiveness. As expected, enprofylline did block NECA-induced bronchoconstriction as reflected by rightward shift of the dose-response curve (Fig. 5) . EC 100 changed from 30.66 g/ml (95% confidence limits: 24.75-36.58) in sensitized and challenged mice to 157.40 g/ml (95% confidence limits: 114.59-200.21) after pretreatment with enprofylline in sensi- tized and challenged mice (P Ͻ 0.01). Also, a combination of enprofylline and MRS1523 completely inhibited the bronchoconstrictor responsiveness to NECA in both groups (Fig. 6) , which was different from the effect of MRS1523 alone on a dose-response curve for NECA (Fig. 4B) , suggesting the involvement of A 2B and A 3 receptors in NECA-induced bronchoconstriction.
Adenosine Receptor Transcript Levels in Mouse Lungs
Adenosine receptor transcript levels were quantified in total RNA extracts isolated from whole lungs of both ragweed-sensitized and -challenged mice and control animals. RT-PCR revealed expression of four subtypes of adenosine receptors in the control lungs, with relatively high levels of A 2B receptor message, intermediate levels of A 1 and A 3 receptor message, and low levels of A 2A receptors (Fig. 7A) . Mice sensitized and challenged with ragweed showed changes in the message for adenosine receptors in lungs. There were significant elevations in transcript levels of A 2B and A 3 receptors after ragweed sensitization and challenge, which increased by 42.58% for A 2B receptors (P Ͻ 0.01) and 29.05% for A 3 receptors (P Ͻ 0.05), respectively, and there was a decrease in the expression of A 1 adenosine receptors by 22.85% (P Ͻ 0.05). Little change in the expression of A 2A receptors was observed (Ϫ4.39%) with a P value Ͼ0.05 (Fig. 7B ).
DISCUSSION
Consistent with our previous study (9) , our present results show that NECA, a nonselective adenosine receptor agonist, causes bronchoconstriction, which is significantly greater in systemically allergen-sensitized, airway-challenged mice compared with control animals. Furthermore, the A 1 agonist CPA and A 2A However, the A 3 agonist CL-IB-MECA induced dosedependent bronchoconstriction, which was completely inhibited by the selective A 3 antagonist MRS1523 (Fig.  4A) . At the same time, NECA-induced bronchoconstriction was partially inhibited by MRS1523, especially at the highest concentration of NECA, indicating the involvement of other adenosine receptors, possibly A 2B receptors. To confirm our observations further, we employed a relatively selective A 2B receptor antagonist, enprofylline, to study the effect of A 2B receptors on NECA-induced bronchoconstriction. Enprofylline showed an attenuation of NECA-induced bronchoconstriction (Fig. 5) . Because enprofylline is a relatively selective A 2B antagonist with K i values of 7 and 65 M for A 2B and A 3 receptors, respectively (10) , it was still difficult to make conclusions about the role of A 2B receptors from this experiment. Further supporting data were obtained using a combination of enprofylline with MRS1523, which showed that the partial inhibition of NECA-induced bronchoconstriction was completely blocked by a combination of enprofylline and MRS1523. These results were supported by the transcript levels of both A 2B and A 3 receptors being higher in the sensitized and challenged mice as opposed to control mice. Together, these results suggest that A 2B and A 3 adenosine receptors are possibly involved in NECA-induced bronchoconstriction in an allergic mouse model.
Adenosine and its agonist-induced bronchoconstriction have been studied in several animal models. A series of studies carried out by Pauwels and colleagues (31, 32) showed that BDE rats respond to adenosine agonists with the following order of potency: NECA ϭ CPA Ͼ N 6 -2-(4-aminophenyl)ethyladenosine Ͼ N 6 -cyclohexyladenosine Ͼ R-N 6 -(2-phenylisopropyl)-adenosine Ͼ CGS21680. In the same study, A 3 -selective agonist produced a dose-dependent bronchoconstriction, and selective A 1 receptor antagonists KF15372 and KW3902 inhibited bronchoconstrictor responsiveness to NECA (31, 32) . These observations led the investigators to conclude that adenosine-induced bronchoconstriction in the BDE rat was most likely through A 1 , A 2B , and A 3 receptors (31, 32) . In Brown Norway rats, Hannon and coworkers (13) suggested the involvement of A 2B receptors in bronchoconstrictor responsiveness to adenosine. The same investigators, in a more recent study, questioned the role of A 2B receptors in the bronchoconstrictor responsiveness to adenosine in Brown Norway rats (14) . Studies using guinea pigs suggest the existence of a mechanism involving adenosine A 3 receptors (18, 38) . In another animal model, the animals immunized neonatally with ragweed or house dust mite developed bronchoconstrictor responsiveness to adenosine agonists (1) . In this model, the order of agonist potency was CPA ϾϾ NECA ϾϾ CGS21680, and CPA-induced bronchoconstrictor responsiveness was blocked by a selective A 1 antagonist, DPCPX (2) . This pharmacological profile is typical of an adenosine A 1 receptor subtype. In an extension of these studies, Nyce and Metzger (28) confirmed that an aerosolized phosphorothiorate antisense oligodeoxynucleotide directed against the A 1 receptors (but not the appropriate sense control) attenuated bronchoconstrictor responsiveness of immunized rabbits to either adenosine or adenosine agonists or dust mite allergen. To the best of our knowledge, the present study demonstrates in mice for the first time that adenosine-and its agonist-induced bronchoconstriction was most likely mediated by the activation of A 2B and A 3 adenosine receptors. Furthermore, an expression of all four subtypes of adenosine receptors was found in normal mouse lung using RT-PCR (Fig. 7A) . Allergen sensitization and airway challenge produced a significant increase in the transcript levels of A 2B and A 3 adenosine receptors in mouse lung (Fig. 7B) .
Whether the effect of receptor activation in this model is a direct effect on airway smooth muscle or secondary to an effect on the activation of other cells (e.g., mast cells, eosinophils, neutrophils, lymphocytes, and macrophages) cannot be determined from this study. However, there is evidence that A 2B adenosine receptors are expressed in human airway smooth muscle cells (26) . Adenosine could directly affect airway smooth muscle cell contractility by modulating the intracellular [Ca 2ϩ ] through the activation of adenosine A 3 receptors (25) . Mice lacking the adenosine A 3 receptors showed attenuation of adenosine-induced bronchoconstriction (39) . The A 1 receptors located directly on the smooth muscle in monkey and rabbit (27, 28) may play a role, since the selective depletion of the airway smooth muscle A 1 receptors by antisense reduced the bronchoconstrictor response to adenosine (28) . However, our data showed a decrease in transcript level for A 1 receptors after allergen sensitization and challenge of mice, as well as the absence of CPAinduced bronchoconstriction in both control and sensitized and challenged mice. This discrepancy may be attributed to the use of a different animal model with varying pathophysiological conditions. A decrease in the expression of adenosine A 1 receptors has been reported in chronic inflammatory disease (16) . Diminished A 1 receptor mRNA in mouse lung in our study may reflect a compensatory mechanism for the lung inflammation, since proinflammatory actions of adenosine A 1 receptor agonists on inflammatory cells have been suggested (7) .
A variety of evidence points to the bronchoconstrictor responsiveness to adenosine being a consequence of activation of inflammatory cells in airways, especially mast cells and eosinophils (40, 41) . It is well documented that A 2A , A 2B , and A 3 receptor mRNA is expressed in mouse bone marrow-derived mast cells (23, 35) . In a functional study, Zhong et al. reported that enprofylline was able to protect ϳ30% of the adenosine-dependent mast cell degranulation in adenosine deaminase (ADA)-deficient mice (41) . These authors further demonstrated with ADA-deficient and A 3 receptor double-knockout mice that A 3 receptors also played an important role in adenosine-mediated murine lung mast cell degranulation (42) . Enhanced expression of adenosine A 3 receptors on eosinophils has also been reported in the asthmatic lung (40) . Our findings of increased expression of A 2B and A 3 adenosine receptors in ragweed-sensitized and -challenged mouse lung was also confirmed by Chunn and colleagues in partially ADA-deficient mouse lung (6) .
In summary, our data show an increased expression of A 2B and A 3 receptor transcripts and no change in A 2A receptor transcript with a decrease in A 1 message in sensitized and challenged mice. Although A 1 /A 2A receptors were expressed in mouse lung, on the basis of Penh they seemed to play a little role in adenosinemediated bronchoconstriction in our studies. Taking these data together, we conclude that adenosine A 2B and A 3 receptors play an important role in adenosineand its agonist-induced bronchoconstriction in our allergic mouse model.
